EORTC PHASE-II STUDY OF CISPLATIN IN CYVADIC-RESISTANT SOFT-TISSUE SARCOMA

被引:27
作者
BRAMWELL, VHC
BRUGAROLAS, A
MOURIDSEN, HT
CHEIX, F
DEJAGER, R
VANOOSTEROM, AT
VENDRIK, CP
PINEDO, HM
SYLVESTER, R
DEPAUW, M
机构
[1] FREE UNIV AMSTERDAM,ACAD ZIEKENHUIS,AMSTERDAM,NETHERLANDS
[2] INST JULES BORDET,SERV MED INTERNE,EORTC DATA CTR,B-1000 BRUSSELS,BELGIUM
[3] FINSEN INST,DEPT R11,DK-2100 COPENHAGEN,DENMARK
[4] ACAD ZIEKENHUIS LEIDEN,DEPT RADIOTHERAPY & MED ONCOL,LEIDEN,NETHERLANDS
[5] CTR LEON BERARD,F-69373 LYON 2,FRANCE
[6] HOSP GEN ASTURIAS,CTR ONCOL POLICLIN,OVIEDO,SPAIN
[7] ACAD ZIEKENHUIS UTRECHT,UTRECHT,NETHERLANDS
关键词
D O I
10.1016/0014-2964(79)90032-X
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Cis-diamminodichloroplatinum (II) (cis-DDP), 100 mg/m2 every 3 weeks was administered to 24 patients with advanced soft tissue sarcoma. All patients had received extensive prior chemotherapy and had measurable progressive disease and normal renal function on entry to the study. There were no objective responses in the 17 patients receiving an adequate trial of therapy. Nausea and vomiting were universal. Renal impairment was moderate in 2 patients and mild in 4. Serial audiometry detected hearing loss at high frequencies in 3 patients. © 1979.
引用
收藏
页码:1511 / 1513
页数:3
相关论文
共 17 条
  • [1] BAUM E, CANCER TREAT REP
  • [2] CVITKOVIC E, 1977, CANCER, V39, P1357, DOI 10.1002/1097-0142(197704)39:4<1357::AID-CNCR2820390402>3.0.CO
  • [3] 2-C
  • [4] EARHART RH, 1978, CANCER TREAT REP, V62, P1105
  • [5] CIS-DIAMMINEDICHLOROPLATINUM, VINBLASTINE, AND BLEOMYCIN COMBINATION CHEMOTHERAPY IN DISSEMINATED TESTICULAR CANCER
    EINHORN, LH
    DONOHUE, J
    [J]. ANNALS OF INTERNAL MEDICINE, 1977, 87 (03) : 293 - 298
  • [6] HAYES DM, 1977, CANCER, V39, P1372, DOI 10.1002/1097-0142(197704)39:4<1372::AID-CNCR2820390404>3.0.CO
  • [7] 2-J
  • [8] HIGBY DJ, 1973, CANCER CHEMOTH REP 1, V57, P459
  • [9] KOVACH JS, 1973, CANCER CHEMOTH REP 1, V57, P357
  • [10] MERRIN C, 1976, P AM ASSOC CANC RES, V17, P243